Literature DB >> 14720207

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.

Peter Klivenyi1, Mahmoud Kiaei, Gabrielle Gardian, Noel Y Calingasan, M Flint Beal.   

Abstract

There is substantial evidence implicating both inflammation and mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS) pathogenesis. We investigated the therapeutic effects of cyclooxygenase 2 (COX-2) inhibitors both alone and in combination with creatine in the G93A transgenic mouse model of ALS. Oral administration of either celecoxib or rofecoxib significantly improved motor performance, attenuated weight loss and extended survival. The administration of COX-2 inhibitors significantly reduced prostaglandin E2 levels at 110 days of age. The combination of creatine with COX-2 inhibitors produced additive neuroprotective effects and extended survival by approximately 30%. The COX-2 inhibitors significantly protected against depletion of anterior horn motor neurons and creatine with COX-2 inhibitors showed greater protection than COX-2 inhibitors alone. These results suggest that combinations of therapies targeting different disease mechanisms may be a useful strategy in the treatment of ALS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720207     DOI: 10.1046/j.1471-4159.2003.02160.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  41 in total

Review 1.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

Review 2.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 3.  Redox modifier genes and pathways in amyotrophic lateral sclerosis.

Authors:  Barrie J Carter; Pervin Anklesaria; Stephanie Choi; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

Review 4.  Therapeutic targets in prostaglandin E2 signaling for neurologic disease.

Authors:  P J Cimino; C Dirk Keene; Richard M Breyer; Kathleen S Montine; Thomas J Montine
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 5.  The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.

Authors:  Sang-Ho Choi; Saba Aid; Francesca Bosetti
Journal:  Trends Pharmacol Sci       Date:  2009-03-09       Impact factor: 14.819

6.  Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.

Authors:  Anil Kumar; Beenta Kumari; Puneet Kumar
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

Review 7.  Inflammation in ALS and SMA: sorting out the good from the evil.

Authors:  Dimitra Papadimitriou; Virginia Le Verche; Arnaud Jacquier; Burcin Ikiz; Serge Przedborski; Diane B Re
Journal:  Neurobiol Dis       Date:  2009-10-13       Impact factor: 5.996

8.  Mitochondrial therapies for Parkinson's disease.

Authors:  Bobby Thomas; M Flint Beal
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 9.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis.

Authors:  Xibin Liang; Qian Wang; Ju Shi; Ludmila Lokteva; Richard M Breyer; Thomas J Montine; Katrin Andreasson
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.